tranScrip Appoints John Ivory as Head of Commercialisation

tranScrip is delighted to announce the appointment of John Ivory as Head of Commercialisation. In this role, John will lead tranScrip’s commercialisation services, strengthening the company’s capability to provide integrated, cross-functional support for clients across the entire product lifecycle.

John brings over 25 years of extensive industry experience, having served in various Sales, Marketing, and Senior Leadership roles at renowned pharmaceutical companies such as AstraZeneca, Elan, Servier, Genzyme, and Sanofi. He is recognised for driving commercial growth, delivering launch excellence, and leading high-performing teams across diverse therapeutic areas, including rare diseases, oncology, cardiovascular, gastrointestinal, and respiratory.

Linda Summerton, Chief Scientific Officer of tranScrip, stated: “At tranScrip, we pride ourselves on our strategic, cross-functional view of drug development. John’s leadership will allow us to further expand our commercial offerings while continuing to provide unparalleled support to our existing clients. We are delighted to welcome him to the team.”

In previous roles, John has successfully launched multiple innovative drugs, managed P&Ls, and activated strategic change initiatives across Europe and beyond. His extensive background includes local and global marketing, market intelligence and forecasting, market development, and sales and marketing operations. He is adept at navigating complex market access and policy environments, particularly in rare diseases – an area where tranScrip has significant expertise.

John Ivory commented on his appointment to tranScrip: “I am excited to join tranScrip and collaborate with a team renowned for its cross-functional approach to drug development. Together, we will leverage our combined expertise to offer clients comprehensive support across the product lifecycle – from early and clinical development to successful market launch and beyond.”

John’s appointment underscores tranScrip’s commitment to expanding its integrated service portfolio, enhancing value for existing clients, and building new partnerships worldwide. By uniting scientific, medical, regulatory, and commercial insights, tranScrip continues to position itself at the forefront of specialist pharmaceutical consulting — enabling clients to maximise the value of their products for the benefit of patients worldwide.

For more insights into our team members, visit Our People.

About tranScrip
tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle – from TRANslation to preSCRIPtion. We exist to enable our clients to maximise the value of their products for the benefit of patients worldwide. For more information, please visit www.transcrip-group.com and follow us on LinkedIn.

Media Contact
Ashton Brooke-Thorne
Senior Marketing Manager
ashton.brooke-thorne@transcrip-group.com